Postdoc – Advanced Viral Vector Technology & Bioprocess Development - Leuven, Belgium
- 6 minutes ago
- 1 min read
Our research group, the Laboratory Molecular Vectorlogy and Gene Therapy (LMVGT) is part of ADVANTAGE labs (Advanced Disease Modeling, Targeted Drug Discovery and Gene Therapy), Dept. Pharmaceutical and Pharmacological Sciences, group Biomedical Sciences at KU Leuven, Belgium.
Our mission is to advance viral vector engineering, technology development, production, and application for rare disease modelling and gene therapy. We work in close partnership with the Leuven Viral Vector Core (LVVC), a fully equipped BSL2 academic viral vector production facility and technology platform for retroviral (RV), lentiviral (LV), recombinant AAV (rAAV) and virus-like particles (VLPs).
Our research spans: (i) Synthetic vectorology and establishment of next-generation viral vector platforms ; (ii) Innovative upstream (USP) and downstream (DSP) bioprocess development for viral vector manufacturing ; (iii) Isogenic disease modelling using patient-derived cells, iPSC and organoid-based systems ; (iv) Gene therapy development for rare genetic disorders.